



### I. Epidemiological profile

Population (UN Population Division)	2012	%
Number of active foci	0	
Number of people living within active foci	-	
Number of people living in malaria-free areas	41 100 000	100
Total	41 100 000	

Parasites and vectors	
Major plasmodium species:	<i>P. falciparum</i> (100%), <i>P. vivax</i> (0%)
Major anopheles species:	<i>An.pseudopunctipennis</i> , <i>darlingi</i>
Programme phase: Pre-elimination	

### II. Intervention policies and strategies



Intervention	Policies/strategies	Yes/No	Year adopted
<b>ITN</b>	ITNs/LLINs distributed free of charge	No	-
	ITNs/LLINs distributed to all age groups	No	-
<b>IRS</b>	IRS is recommended	Yes	-
	DDT is used for IRS	No	-
<b>Larval control</b>	Use of larval control	No	-
<b>IPT</b>	IPT used to prevent malaria during pregnancy	N/A	-
<b>Diagnosis</b>	Patients of all ages should receive diagnostic test	Yes	-
	Malaria diagnosis is free of charge in the public sector	Yes	1980
<b>Treatment</b>	ACT is free for all ages in public sector	Yes	-
	Artemisinin-based monotherapies withdrawn	-	-
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for <i>P. falciparum</i>	-	-
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	Yes	-
	System for monitoring of adverse reaction to antimalarials exists	Yes	-

Intervention	Policies/strategies	Yes/No	Year adopted
<b>Surveillance</b>	ACD for case investigation (reactive)	Yes	-
	ACD at community level of febrile cases (pro-active)	No	-
	Mass screening is undertaken	Yes	-
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-
	Foci and case investigation undertaken	Yes	-
	Case reporting from private sector is mandatory	Yes	-



Antimalaria treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	-	-
First-line treatment of <i>P. falciparum</i>	AL	-
For treatment failure of <i>P. falciparum</i>	-	-
Treatment of severe malaria	-	-
Treatment of <i>P. vivax</i>	CQ+PQ	-
Dosage of primaquine for radical treatment of <i>P. vivax</i>	0.25 mg/kg (14 days)	-

Therapeutic efficacy tests (clinical and parasitological failure, %)							
Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species





### III. Financing



### IV. Coverage



### V. Impact



**Impact:** On track for >75% decrease in incidence 2000–2015